These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 3094196

  • 1. Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity.
    Bruner LH, Carpenter LJ, Hamlow P, Roth RA.
    Toxicol Appl Pharmacol; 1986 Sep 30; 85(3):416-27. PubMed ID: 3094196
    [Abstract] [Full Text] [Related]

  • 2. Platelets and the puzzles of pulmonary pyrrolizidine poisoning.
    Roth RA, Ganey PE.
    Toxicol Appl Pharmacol; 1988 May 30; 93(3):463-71. PubMed ID: 3130680
    [Abstract] [Full Text] [Related]

  • 3. Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite.
    Roth RA, Reindel JF.
    Adv Exp Med Biol; 1991 May 30; 283():477-87. PubMed ID: 1906225
    [Abstract] [Full Text] [Related]

  • 4. The effect of dietary restriction and altered sodium intake on the cardiopulmonary toxicity of monocrotaline pyrrole.
    Ganey PE, Fink GD, Roth RA.
    Toxicol Appl Pharmacol; 1985 Mar 30; 78(1):55-62. PubMed ID: 2930913
    [Abstract] [Full Text] [Related]

  • 5. Early indications of monocrotaline pyrrole-induced lung injury in rats.
    Schultze AE, Wagner JG, White SM, Roth RA.
    Toxicol Appl Pharmacol; 1991 Jun 01; 109(1):41-50. PubMed ID: 2038748
    [Abstract] [Full Text] [Related]

  • 6. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats.
    White SM, Wagner JG, Roth RA.
    Toxicol Appl Pharmacol; 1989 Jun 15; 99(2):302-13. PubMed ID: 2734793
    [Abstract] [Full Text] [Related]

  • 7. COR pulmonale is caused by monocrotaline and dehydromonocrotaline, but not by glutathione or cysteine conjugates of dihydropyrrolizine.
    Pan LC, Wilson DW, Lamé MW, Jones AD, Segall HJ.
    Toxicol Appl Pharmacol; 1993 Jan 15; 118(1):87-97. PubMed ID: 8430429
    [Abstract] [Full Text] [Related]

  • 8. An evaluation of procoagulant activity in the peripheral blood of rats treated with monocrotaline pyrrole.
    Schultze AE, Wagner JG, Roth RA.
    Toxicol Appl Pharmacol; 1991 Jul 15; 109(3):421-31. PubMed ID: 1830177
    [Abstract] [Full Text] [Related]

  • 9. Injury to the isolated, perfused lung by exposure in vitro to monocrotaline pyrrole.
    Hilliker KS, Roth RA.
    Exp Lung Res; 1985 Jul 15; 8(4):201-12. PubMed ID: 4043006
    [Abstract] [Full Text] [Related]

  • 10. Complement is not involved in monocrotaline pyrrole-induced pulmonary injury.
    Bruner LH, Johnson KJ, Till GO, Roth RA.
    Am J Physiol; 1988 Feb 15; 254(2 Pt 2):H258-64. PubMed ID: 3344816
    [Abstract] [Full Text] [Related]

  • 11. Strain differences in the response of Fischer 344 and Sprague-Dawley rats to monocrotaline induced pulmonary vascular disease.
    Pan LC, Wilson DW, Segall HJ.
    Toxicology; 1993 Mar 30; 79(1):21-35. PubMed ID: 8475497
    [Abstract] [Full Text] [Related]

  • 12. Bioactivation of monocrotaline by P-450 3A in rat liver.
    Kasahara Y, Kiyatake K, Tatsumi K, Sugito K, Kakusaka I, Yamagata S, Ohmori S, Kitada M, Kuriyama T.
    J Cardiovasc Pharmacol; 1997 Jul 30; 30(1):124-9. PubMed ID: 9268231
    [Abstract] [Full Text] [Related]

  • 13. The effect of immunosuppressants and adoptive transfer in monocrotaline pyrrole pneumotoxicity.
    Bruner LH, Bull RW, Roth RA.
    Toxicol Appl Pharmacol; 1987 Oct 30; 91(1):1-12. PubMed ID: 3672514
    [Abstract] [Full Text] [Related]

  • 14. Lack of effect of deferoxamine, dimethyl sulfoxide, and catalase on monocrotaline pyrrole pulmonary injury.
    Bruner LH, Johnson K, Carpenter LJ, Roth RA.
    J Toxicol Environ Health; 1987 Oct 30; 21(1-2):205-17. PubMed ID: 3573071
    [Abstract] [Full Text] [Related]

  • 15. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension.
    Hilliker KS, Bell TG, Lorimer D, Roth RA.
    Am J Physiol; 1984 Jun 30; 246(6 Pt 2):H747-53. PubMed ID: 6742140
    [Abstract] [Full Text] [Related]

  • 16. Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone.
    Hilliker KS, Roth RA.
    Br J Pharmacol; 1984 Jun 30; 82(2):375-80. PubMed ID: 6234044
    [Abstract] [Full Text] [Related]

  • 17. Effects of monocrotaline and monocrotaline pyrrole on 5-hydroxytryptamine and paraquat uptake by lung slices.
    Hilliker KS, Garcia CM, Roth RA.
    Res Commun Chem Pathol Pharmacol; 1983 May 30; 40(2):179-97. PubMed ID: 6410470
    [Abstract] [Full Text] [Related]

  • 18. Effects of monocrotaline pyrrole on cultured rat pulmonary endothelium.
    Hoorn CM, Wagner JG, Roth RA.
    Toxicol Appl Pharmacol; 1993 Jun 30; 120(2):281-7. PubMed ID: 8511798
    [Abstract] [Full Text] [Related]

  • 19. Cellular fibronectin and von Willebrand factor concentrations in plasma of rats treated with monocrotaline pyrrole.
    Schultze AE, Emeis JJ, Roth RA.
    Biochem Pharmacol; 1996 Jan 26; 51(2):187-91. PubMed ID: 8615888
    [Abstract] [Full Text] [Related]

  • 20. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
    Ganey PE, Sprugel KH, Hadley KB, Roth RA.
    J Pharmacol Exp Ther; 1986 Apr 26; 237(1):226-31. PubMed ID: 2937908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.